IPF-026

Idiopathic Pulmonary Fibrosis (IPF)

Guangzhou 64 years old male China Total Cost: 215

Patient Condition

The patient sought medical treatment due to dry cough and shortness of breath after exercise for 1 year. HRCT showed grid shadows and honeycomb changes in both lower lungs. Lung function: FVC 62% predicted, DLCO 48% predicted. 6MWD 370m, mMRC score 2. IPF was diagnosed (GAP score 3, stage I).

Treatment Timeline

PhaseDetailsDate
diagnostic assessment
treatment initiation
Standardized treatment (months 1-12)
Maintenance treatment (Months 13-24)

Treatment Outcome

beforeFVC accounted for 62% of predicted value, DLCO accounted for 48% of predicted value, 6MWD 370m, mMRC score 2
afterAfter 24 months of treatment, FVC accounted for 58% of the predicted value (annual decline rate of approximately 2%), DLCO accounted for 44% of the predicted value, 6MWD 375m, and mMRC score 2
highlightPirfenidone treatment for 24 months effectively delayed the progression of IPF, with an annual decline in FVC of approximately 2%, which was well tolerated by patients